Celldex Therapeutics, Inc. Marketable Securities, Unrealized Gain (Loss)
Celldex Therapeutics, Inc. (CLDX) reported Marketable Securities, Unrealized Gain (Loss) of -$536.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2026-08-06
- Celldex Therapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2026-06-30 was -$711.30M, a 2640.36% decline year-over-year.
- Celldex Therapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2026-03-31 was $174.40M, a 39.30% increase year-over-year.
- Celldex Therapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2025-12-31 was -$52.90M, a 146.44% decline year-over-year.
- Celldex Therapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2025-09-30 was -$119.70M.
- Celldex Therapeutics, Inc. marketable securities, unrealized gain (loss) for fiscal 2024 was $142.50M, a 77.24% increase from fiscal 2023.
- Celldex Therapeutics, Inc. marketable securities, unrealized gain (loss) for fiscal 2023 was $80.40M, a 39.96% decline from fiscal 2022.
- Celldex Therapeutics, Inc. marketable securities, unrealized gain (loss) for fiscal 2022 was $133.90M.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 12 month | Marketable Securities, Unrealized Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$711.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$536.90M 10-Q · filed 2026-08-06 | -$589.80M derived: sum of 3 quarters · filed 2026-08-06 | -$709.50M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $174.40M 10-Q · filed 2026-05-07 | $121.50M derived: sum of 2 quarters · filed 2026-08-06 | $1.80M derived: sum of 3 quarters · filed 2026-08-06 | $29.80M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | -$52.90M derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-06 | -$172.60M derived: sum of 2 quarters · filed 2026-08-06 | -$144.60M derived: sum of 3 quarters · filed 2026-08-06 | -$19.40M 10-Q · filed 2026-08-06 | $19.40M 10-K · filed 2026-02-25 |
| 2025-09-30 | -$119.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$91.70M derived: sum of 2 quarters · filed 2025-11-10 | $33.50M 10-Q · filed 2025-11-10 | $147.40M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2025-06-30 | $28.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $153.20M 10-Q · filed 2025-08-07 | $267.10M derived: sum of 3 quarters · filed 2026-02-25 | -$318.70M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2025-03-31 | $125.20M 10-Q · filed 2025-05-08 | $239.10M derived: sum of 2 quarters · filed 2026-02-25 | -$346.70M derived: sum of 3 quarters · filed 2026-02-25 | -$190.40M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-12-31 | $113.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$471.90M derived: sum of 2 quarters · filed 2026-02-25 | -$315.60M derived: sum of 3 quarters · filed 2026-02-25 | $142.50M 10-K · filed 2026-02-25 | |
| 2024-09-30 | -$585.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$429.50M derived: sum of 2 quarters · filed 2024-11-06 | $28.60M 10-Q · filed 2024-11-06 | ||
| 2024-06-30 | $156.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $614.40M 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $458.10M 10-Q · filed 2024-05-06 | ||||
| 2023-12-31 | $80.40M 10-K · filed 2025-02-27 | ||||
| 2022-12-31 | $133.90M 10-K · filed 2024-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |